Jane Street Group LLC purchased a new position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN – Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 19,659 shares of the company’s stock, valued at approximately $59,000.
Several other hedge funds have also recently made changes to their positions in VTGN. Blair William & Co. IL boosted its holdings in shares of Vistagen Therapeutics by 29.2% during the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after buying an additional 20,000 shares in the last quarter. Valence8 US LP bought a new stake in shares of Vistagen Therapeutics during the third quarter worth about $103,000. American Century Companies Inc. boosted its position in shares of Vistagen Therapeutics by 49.1% during the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after buying an additional 9,984 shares during the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of Vistagen Therapeutics during the third quarter valued at about $64,000. 78.39% of the stock is owned by institutional investors.
Vistagen Therapeutics Trading Up 4.6 %
Shares of VTGN opened at $2.97 on Thursday. The stock has a 50 day moving average of $2.75 and a 200 day moving average of $3.11. The company has a market capitalization of $82.69 million, a price-to-earnings ratio of -2.40 and a beta of 0.78. Vistagen Therapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $5.74.
About Vistagen Therapeutics
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Featured Articles
- Five stocks we like better than Vistagen Therapeutics
- When to Sell a Stock for Profit or Loss
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- How Do Stock Buybacks Affect Shareholders?
- What is a Low P/E Ratio and What Does it Tell Investors?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Want to see what other hedge funds are holding VTGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vistagen Therapeutics, Inc. (NASDAQ:VTGN – Free Report).
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
